home / stock / cdmop / cdmop news

CDMOP News and Press, Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock From 09/01/20

Stock Information
Company Name: Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock
Stock Symbol: CDMOP
Market: NASDAQ
Website: avidbio.com
Menu
CDMOP CDMOP Quote CDMOP Short CDMOP News CDMOP Articles CDMOP Message Board
Get CDMOP Alerts

News, Short Squeeze, Breakout and More Instantly...
CDMOP - Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q1 2021 Results - Earnings Call Transcript

Avid Bioservices, Inc. (CDMO) Q1 2021 Earnings Conference Call September 01, 2020 04:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and CEO Dan Hart - Chief Financial Officer Timothy Compton - Chief Commercial Officer Conference Call Part...
CDMOP - Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developments

-- Recorded First Quarter Revenue of $25.4 Million -- -- S igned Three New Customers and Project Expansion Orders with Current Customers for $20 Million -- -- Backlog of $60 Million at Quarter-End -- TUSTIN, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc.&#x...

CDMOP - Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody

TUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to b...

CDMOP - Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2021 After Market Close on September 1, 2020

TUSTIN, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical com...
CDMOP - Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine

Avid Well Positioned to Meet Significant Scale-Up Requirements for NIH-Licensed SARS-CoV-2 Spike Protein Vaccine Candidate Oragenics, Inc. (NYSE American: OGEN) and Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that the companies have entered into a process deve...

CDMOP - Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001

TUSTIN, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to b...

CDMOP - Avid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Parenteral Manufacturing

TUSTIN, Calif. and CARLSBAD, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufa...
CDMOP - Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q4 2020 Results - Earnings Call Transcript

Avid Bioservices, Inc. (CDMO) Q4 2020 Earnings Conference Call June 30, 2020, 04:30 PM ET Company Participants Tim Brons - IR Richard Hancock - Interim President and CEO Daniel Hart - CFO Timothy Compton - Chief Commercial Officer Conference Call Participants Matt Hewitt ...

CDMOP - Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments

-- Appointed Nicholas Green as President and Chief Executive Officer -- -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million -- -- S igned $23 Million in Business Orders and A chieved Record Backlog of $65 Million  During the Fourth Quarte...

CDMOP - Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020

TUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical com...
Previous 10 Next 10